background
middl
east
respiratori
syndrom
mer
coronaviru
caus
isol
case
outbreak
sever
respiratori
diseas
essenti
featur
natur
histori
diseas
poorli
understood
method
studi
adult
patient
infect
mer
coronaviru
viral
load
lower
upper
respiratori
tract
lrt
urt
respect
blood
stool
urin
antibodi
serum
neutral
activ
determin
cours
diseas
result
one
hundr
ninetynin
lrt
sampl
collect
week
follow
diagnosi
yield
viru
rna
test
averag
maximum
viral
load
copiesml
viral
load
posit
detect
frequenc
urt
sampl
copiesml
thirtythre
percent
serum
sampl
test
yield
viral
rna
stool
urin
sampl
yield
viral
rna
seroconvers
occur
first
week
diagnosi
correspond
second
third
week
symptom
onset
immunoglobulin
detect
provid
advantag
sensit
immunoglobulin
g
igg
detect
surviv
patient
slightli
half
fatal
case
produc
igg
neutral
antibodi
level
igg
neutral
antibodi
weakli
invers
correl
lrt
viral
load
presenc
antibodi
lead
elimin
viru
lrt
conclus
time
intens
respiratori
viral
shed
patient
mer
close
match
sever
acut
respiratori
syndrom
blood
viral
rna
seem
infecti
extrapulmonari
loci
viru
replic
seem
possibl
neutral
antibodi
suffic
clear
infect
middl
east
respiratori
syndrom
coronaviru
merscov
first
isol
saudi
arabia
sinc
least
laboratoryconfirm
case
merscov
infect
mostli
respiratori
tract
ill
report
fatal
known
case
outbreak
link
countri
arabian
peninsula
larg
nosocomi
outbreak
jeddah
kingdom
saudi
arabia
republ
korea
demonstr
potenti
viru
spread
healthcar
set
due
sporad
natur
diseas
case
small
outbreak
distribut
wide
geograph
area
investig
natur
histori
infect
limit
except
individu
case
descript
chronolog
data
summar
main
viral
diagnost
paramet
viral
load
antibodi
lack
better
knowledg
kinet
viral
shed
differ
bodi
region
could
help
prevent
nosocomi
transmiss
inform
clinic
manag
knowledg
serolog
featur
kinet
antibodi
product
could
guid
decis
regard
diagnost
protocol
provid
essenti
inform
regard
immun
viru
elimin
quantit
data
viral
load
antibodi
titer
could
enabl
comparison
relat
diseas
particular
sever
acut
respiratori
syndrom
sar
studi
natur
histori
conduct
aftermath
epidem
patient
seen
hospitalassoci
outbreak
march
may
prospect
plan
statist
power
patient
select
merscov
test
revers
transcript
polymeras
chain
reaction
rtpcr
base
gener
clinic
condit
oxygen
satur
need
invas
noninvas
ventil
sampl
patient
test
posit
taken
least
daili
start
day
initi
submiss
sampl
merscov
diagnosi
day
first
sampl
test
posit
rtpcr
defin
day
diagnosi
mean
delay
first
posit
sampl
return
laboratori
result
day
store
sampl
retrospect
analysi
avail
specimen
taken
tracheal
secret
via
suction
cathet
throat
eye
use
steril
swab
urin
stool
via
steril
contain
baselin
inform
enrol
patient
provid
supplementari
tabl
institut
review
board
approv
obtain
research
ethic
committe
princ
sultan
militari
medic
citi
realtim
rtpcr
perform
rna
extract
use
upe
target
gene
describ
raw
rna
concentr
transform
absolut
viral
load
convers
factor
accord
sampl
type
supplementari
tabl
viru
isol
increas
sensit
via
use
human
colon
carcinoma
cell
perform
describ
recombin
enzymelink
immunosorb
assay
elisa
antimerscov
elisa
igg
euroimmun
germani
base
solubl
merscov
spike
protein
domain
express
cell
test
conduct
describ
previous
sera
test
twice
arithmet
mean
measur
use
detect
immunoglobulin
igm
antibodi
done
use
immunofluoresc
slide
carri
vero
cell
infect
full
merscov
describ
corman
et
al
convert
homogen
reagent
format
vitro
diagnost
manufactur
antimerscoviift
euroimmun
sera
deplet
immunoglobulin
g
igg
antibodi
use
eurosorb
euroimmun
reagent
accord
manufactur
instruct
merscov
microneutr
test
nt
perform
describ
predilut
set
log
dilut
seri
defin
lowest
possibl
signific
titer
categor
sampl
posit
statist
analys
done
use
spss
softwar
version
case
correl
analys
preliminari
multipl
regress
analys
conduct
exclud
confound
due
patient
age
diseas
durat
determin
kinet
virolog
paramet
merscov
infect
follow
hospit
patient
mean
age
year
rang
year
patient
male
merscov
infect
establish
case
rtpcr
sixtyf
percent
patient
die
cours
studi
sequenc
full
partial
genom
studi
patient
reveal
exist
least
close
relat
viru
lineag
supplementari
figur
tabl
sequenc
alreadi
seen
earlier
studi
patient
belong
least
nosocomi
transmiss
cluster
three
case
could
associ
cluster
time
posit
diagnosi
patient
spent
day
hospit
averag
maximum
day
patient
hospit
less
week
unresolv
time
transmiss
event
nosocomi
cluster
exist
comorbid
patient
imposs
determin
day
onset
symptom
major
patient
unambigu
knowledg
day
onset
symptom
avail
patient
mean
median
durat
symptom
onset
admiss
day
rang
day
case
mean
median
durat
onset
diagnosi
day
rang
day
mean
age
case
significantli
differ
mean
age
patient
studi
provid
common
point
refer
clinic
cours
patient
day
diagnosi
day
first
rtpcrposit
sampl
defin
day
subsequ
analys
eight
hundr
twentythre
specimen
patient
test
includ
test
viral
load
differ
sampl
categori
supplementari
tabl
variabl
latenc
diagnosi
enrol
clinic
sampl
evenli
distribut
patient
cours
diseas
supplementari
figur
absolut
viral
rna
concentr
posit
proport
sampl
determin
sampl
data
illustr
figur
supplementari
tabl
lower
respiratori
tract
lrt
sampl
highest
viral
load
copiesml
mean
copiesml
averag
viral
load
sampl
type
significantli
lower
test
p
comparison
viru
isol
trial
use
stool
sampl
highest
rna
concentr
neg
outcom
almost
half
sera
show
detect
viral
load
first
week
diagnosi
sera
test
viru
isol
virem
serum
sampl
without
neutral
antibodi
fail
despit
highli
optim
protocol
invers
correl
vitro
serum
neutral
activ
viremia
sera
pearson
r
p
howev
viral
rna
neutral
antibodi
codetect
sever
case
suggest
detect
viral
rna
may
part
repres
infecti
virion
figur
concentr
rna
serum
correl
significantli
lrt
sampl
collect
day
n
pair
serum
lrt
sampl
spearman
correl
p
figur
distribut
averag
lrt
viral
load
per
patient
summar
subsequ
time
window
figur
particular
first
day
diagnosi
averag
viral
load
normal
distribut
skew
distribut
preponder
patient
high
viral
load
note
patient
highest
viral
load
categori
rightmost
column
top
panel
figur
show
significantli
increas
proport
fatal
outcom
test
p
averag
viral
load
first
week
diagnosi
copiesml
fatal
case
copiesml
survivor
test
p
diverg
viral
load
survivor
fatal
case
pronounc
second
week
copiesml
respect
p
serolog
cours
could
follow
patient
almost
half
n
alreadi
reactiv
via
elisa
day
diagnosi
among
patient
complet
serolog
followup
first
week
diagnosi
n
antibodi
end
week
elisa
neutral
test
eighteen
patient
test
posit
igm
immunofluoresc
assay
ifa
titer
end
week
igmposit
patient
concomit
posit
elisa
result
end
week
patient
week
serolog
followup
seroconvert
elisa
neutral
test
eleven
patient
develop
igm
detect
ifa
antibodi
kinet
averag
sampl
test
summar
figur
inform
outcom
avail
patient
serolog
followup
patient
surviv
infect
show
seroconvers
elisa
nt
first
week
develop
igm
antibodi
concomitantli
among
fatal
case
show
seroconvers
elisa
prior
death
latest
seroconvers
occur
day
postdiagnosi
twelv
fatal
case
develop
neutral
antibodi
develop
detect
igm
antibodi
level
elisa
optic
densiti
od
log
nt
titer
first
week
diagnosi
significantli
differ
surviv
fatal
case
test
p
second
week
diagnosi
averag
elisa
od
valu
survivor
significantli
higher
fatal
case
vs
test
p
also
averag
nt
titer
higher
survivor
week
less
signific
discrimin
vs
survivor
fatal
case
respect
test
p
elisa
od
valu
log
nt
titer
compar
log
viral
load
lrt
sampl
patient
elisa
viral
load
data
avail
base
match
serum
respiratori
tract
sampl
taken
day
match
data
pair
cover
day
postdiagnosi
workload
biosafeti
number
nt
assay
restrict
howev
combin
elisa
nt
viral
load
data
avail
patient
match
dataset
cover
day
diagnosi
supplementari
figur
summar
distribut
match
sampl
time
pearson
test
identifi
signific
linear
correl
antibodi
log
viral
load
elisa
r
nt
r
p
analys
howev
plot
elisa
nt
antibodi
result
match
sampl
pair
yield
evid
mutual
exclus
occurr
viru
antibodi
figur
discuss
studi
quantit
viral
excret
serum
antibodi
kinet
substanti
group
hospit
patient
infect
merscov
time
diagnosi
chosen
chronolog
refer
point
repres
time
infect
suspect
hospit
patient
outpati
report
hospit
due
worsen
symptom
even
though
day
onset
unknown
mani
studi
case
present
virolog
cours
repres
typic
situat
encount
mer
treatment
hospit
set
provid
absolut
quantit
measur
viru
excret
first
time
compar
result
mer
sar
diseas
thought
involv
higher
pandem
potenti
mer
patient
elsewher
lrt
found
main
sourc
merscov
excret
unfortun
data
lrt
viru
excret
sarscov
endotrach
sampl
wide
discourag
sar
outbreak
avoid
nosocomi
risk
shown
one
avail
studi
sarscov
excret
lrt
mean
concentr
copiesml
reach
maximum
copiesml
studi
conduct
similar
clinic
context
treatment
center
singapor
similar
time
sampl
clinic
cours
determin
viral
load
perform
laboratori
use
equival
calibr
convers
factor
comparison
conclud
averag
peak
lrt
viral
load
mer
equal
sar
data
avail
upper
respiratori
tract
urt
viral
load
sar
patient
peak
urt
rna
concentr
reach
copiessampl
day
onset
correspond
number
mer
peak
copiessampl
equival
higher
also
proport
posit
mer
urt
exceed
proport
posit
urt
sampl
sar
patient
hong
kong
time
excret
difficult
compar
mani
patient
studi
sar
outpati
enter
hospit
sar
infect
wherea
mer
patient
mostli
inpati
sar
case
occur
hong
kong
author
start
activ
commun
contact
trace
averag
time
symptom
onset
admiss
day
case
definit
diagnost
wellestablish
sar
hong
kong
diagnost
sampl
would
taken
immedi
upon
admiss
align
time
studi
base
subcohort
patient
onset
symptom
could
reliabl
determin
patient
time
onset
symptom
initi
laboratori
diagnost
day
similar
earli
hong
kong
sar
case
shed
peak
sar
patient
occur
approxim
day
symptom
onset
similar
shed
maximum
observ
studi
assumpt
day
first
diagnosi
mer
case
plausibl
fall
around
eighth
day
symptom
ie
directli
admiss
summari
neither
viru
concentr
time
respiratori
shed
provid
explan
differ
transmiss
merscov
sarscov
experiment
data
suggest
higher
sensit
merscov
respiratori
epitheliumassoci
type
interferon
might
provid
plausibl
explan
lower
transmiss
comparison
sarscov
mani
explan
possibl
howev
detect
merscov
serum
anoth
similar
sar
serum
sampl
found
contain
sarscov
rna
first
week
ill
around
second
week
number
match
observ
mer
free
viremia
seem
unlik
caus
nosocomi
transmiss
mer
infecti
viru
isol
serum
evid
sarscov
replic
peripher
blood
mononuclear
cell
macrophag
dendrit
cell
albeit
low
level
present
studi
absenc
correl
serum
viral
load
lrt
viral
load
point
potenti
extrapulmonari
replic
viremia
despit
presenc
neutral
antibodi
indic
bodi
region
access
neutral
antibodi
releas
viru
blood
sarscov
shown
replic
sever
extrapulmonari
organ
without
evid
tissu
damag
one
organ
implic
mer
kidney
kidney
failur
report
mani
case
merscov
origin
isol
kidney
cell
express
merscov
entri
receptor
howev
earlier
healthcareassoci
outbreak
center
near
dialysi
center
nephrolog
depart
affect
metabol
compromis
patient
predispos
kidney
failur
suffer
system
diseas
affect
blood
pressur
circul
although
patient
sarscov
show
viral
rna
detect
rate
urin
rare
found
urineassoci
merscov
rna
studi
sar
kidney
failur
mer
patient
might
well
explain
sever
inflammatori
reaction
combin
administr
potenti
nephrotox
drug
intens
care
nevertheless
highli
import
conduct
postmortem
examin
particularli
kidney
patient
die
acut
merscov
infect
clear
differ
sar
detect
viral
rna
stool
sar
rna
preval
stool
sampl
high
test
stool
propos
reliabl
sensit
way
routin
diagnos
diseas
activ
replic
gut
live
viru
isol
demonstr
mer
found
stoolassoci
rna
sampl
rather
low
rna
concentr
success
isol
infecti
viru
base
data
fecal
excret
may
play
relev
role
nosocomi
spread
merscov
among
patient
studi
sar
merscov
nosocomi
transmiss
repeatedli
ascrib
potenti
patient
act
supershedd
superspread
analysi
viral
load
particularli
earli
acut
phase
diseas
support
exist
limit
number
patient
extraordinarili
high
viral
load
patient
like
die
infect
might
sever
symptom
thu
might
abl
engag
social
contact
despit
diseas
cours
mer
antibodi
develop
resembl
sar
patient
infect
sar
seroconvert
week
onset
patient
studi
alreadi
seroconvert
first
week
diagnosi
put
repres
second
week
onset
sar
igm
detect
earlier
igg
limit
diagnost
util
particular
consid
igm
preval
human
coronavirus
may
crossreact
merscov
current
methodolog
igm
test
restrict
case
requir
proof
recent
overcom
merscov
infect
inform
prognost
valu
antibodi
respons
sar
less
clear
present
studi
mer
elisa
nt
fatal
case
fail
mount
antibodi
respons
prior
death
howev
differ
becam
appar
second
week
diagnosi
point
weak
protect
effect
lung
diseas
develop
antibodi
serum
follow
rapid
elimin
viral
rna
lung
neutral
antibodi
normal
includ
immunoglobulin
iga
secret
respiratori
fluid
saliva
recent
shown
antimerscov
iga
inde
secret
respiratori
fluid
suggest
develop
iga
come
late
confer
time
reduct
viral
replic
infect
mucosa
base
data
vaccin
merscov
design
includ
enhanc
cellular
immun
respons
supplementari
materi
avail
http
cidoxfordjournalsorg
consist
data
provid
author
benefit
reader
post
materi
copyedit
sole
respons
author
question
comment
address
author
